HOUSTON, Feb. 14 /PRNewswire/ -- CardioSoft announced today it has completed initial assessments and will proceed with commercialization of a novel High Frequency QRS Electrocardiogram (ECG) technology (HFQRS-ECG) through exclusive licensing from NASA. The technology, comprised of sophisticated software algorithms co-developed by CardioSoft and researchers at NASA's Johnson Space Center, holds promise to enable a new and highly accurate diagnostic tool for use by physicians treating those with ischemic heart disease.

"We are very excited about commercializing this innovative technology, because it can have a real impact on the diagnosis and management of a major cause of morbidity and mortality in modern society," said CardioSoft co- founder Saeed Moradi. Heart disease has long been the number one cause of death in America, with over three-quarter million lives lost every year. In the U.S. alone there are more than 75 million ecgs performed annually.

The HFQRS-ECG software algorithms measure, in real time, signals present in the QRS complex, or heart muscle depolarization phase, of the electrocardiogram. These signals are unrecognized by current ecg methods. "Our development efforts will enable a highly accurate, five-minute resting test that can be readily obtained whenever and wherever conventional ecg is performed," Moradi added. Improved accuracy of HFQRS compared with conventional ecg has already been demonstrated in over 800 patients studied to date by leading researchers. These results have been recently published in several peer-reviewed medical journals.

CardioSoft is also developing additional clinical tools to improve the lives of people at risk for heart disease. The company was founded in 2004 by a team of physicians, engineers and high-tech medical entrepreneurs.

CardioSoft(R) is a privately held pioneering medical technology company building new ecg products designed to improve the diagnosis and management of heart disease. Recognizing key opportunities to enhance electrocardiology, CardioSoft applies its core expertise in digital signal processing to create innovative solutions to meaningful clinical problems.

This press release is provided in good-faith by Chiltern Magazine Services Ltd ("CMS") as a service to users. Whilst every care is taken in sourcing and preparing material included here, any error or incorrect content cannot form the basis for any legal action against the site-owner. Users are advised to check the accuracy of any statements before relying upon them. Likewise, any forward-looking statements made by the author of the press release should be treated as such.

For full details, please email keithw@cmsinfo.com